Li Watsek
Stock Analyst at Cantor Fitzgerald
(1.10)
# 3,513
Out of 4,826 analysts
80
Total ratings
34.94%
Success rate
-23.83%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Li Watsek
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZLAB Zai Lab | Reiterates: Overweight | n/a | $30.95 | - | 1 | Mar 27, 2025 | |
| ACRV Acrivon Therapeutics | Reiterates: Overweight | n/a | $1.41 | - | 2 | Mar 26, 2025 | |
| TARA Protara Therapeutics | Initiates: Overweight | n/a | $3.43 | - | 1 | Mar 14, 2025 | |
| ASND Ascendis Pharma | Maintains: Overweight | $170 → $200 | $170.74 | +17.14% | 17 | Feb 25, 2025 | |
| ARVN Arvinas | Reiterates: Overweight | n/a | $7.63 | - | 5 | Feb 7, 2025 | |
| ALXO ALX Oncology Holdings | Reiterates: Overweight | n/a | $0.53 | - | 7 | Jan 24, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Overweight | n/a | $20.50 | - | 2 | Jan 13, 2025 | |
| KURA Kura Oncology | Reiterates: Overweight | n/a | $6.73 | - | 10 | Dec 9, 2024 | |
| AFMD Affimed | Reiterates: Overweight | n/a | $0.83 | - | 7 | Nov 19, 2024 | |
| RCUS Arcus Biosciences | Reiterates: Overweight | n/a | $8.93 | - | 4 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $20 | $4.26 | +369.48% | 2 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $9.08 | - | 5 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.45 | - | 1 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $3.57 | - | 5 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.71 | +75.44% | 4 | Nov 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $220 | $9.72 | +2,164.54% | 3 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $1.17 | +327.35% | 3 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $38 | $1.99 | +1,814.36% | 1 | Aug 12, 2022 |
Zai Lab
Mar 27, 2025
Reiterates: Overweight
Price Target: n/a
Current: $30.95
Upside: -
Acrivon Therapeutics
Mar 26, 2025
Reiterates: Overweight
Price Target: n/a
Current: $1.41
Upside: -
Protara Therapeutics
Mar 14, 2025
Initiates: Overweight
Price Target: n/a
Current: $3.43
Upside: -
Ascendis Pharma
Feb 25, 2025
Maintains: Overweight
Price Target: $170 → $200
Current: $170.74
Upside: +17.14%
Arvinas
Feb 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $7.63
Upside: -
ALX Oncology Holdings
Jan 24, 2025
Reiterates: Overweight
Price Target: n/a
Current: $0.53
Upside: -
IDEAYA Biosciences
Jan 13, 2025
Reiterates: Overweight
Price Target: n/a
Current: $20.50
Upside: -
Kura Oncology
Dec 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $6.73
Upside: -
Affimed
Nov 19, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.83
Upside: -
Arcus Biosciences
Oct 7, 2024
Reiterates: Overweight
Price Target: n/a
Current: $8.93
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: $20
Current: $4.26
Upside: +369.48%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $9.08
Upside: -
May 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.45
Upside: -
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $3.57
Upside: -
Nov 22, 2023
Reiterates: Overweight
Price Target: $3
Current: $1.71
Upside: +75.44%
Sep 7, 2023
Reiterates: Overweight
Price Target: $220
Current: $9.72
Upside: +2,164.54%
Sep 7, 2023
Reiterates: Neutral
Price Target: $5
Current: $1.17
Upside: +327.35%
Aug 12, 2022
Maintains: Overweight
Price Target: $60 → $38
Current: $1.99
Upside: +1,814.36%